Optimizing antivirals for immunocompromised COVID-19 patients
Part of Immune system & allergy, Infections, Lungs & breathing clinical trials.
This trial tests whether an optimized antiviral treatment can help people with weakened immune systems who have COVID-19. It aims to find the best way to treat them to prevent severe illness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a positive COVID-19 test (PCR or antigen).
- You are 16 years or older.
- Your symptoms are mild or you have no symptoms (you are not on oxygen for COVID-19).
- Your immune system is weakened due to a condition or treatment (like cancer, transplant, HIV, long-term steroids, etc.).
- You are willing to follow the study rules and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the best combination and timing of antiviral medicines for people with COVID-19 who have weakened immune systems. It aims to improve outcomes in people with mild to moderate illness.
This trial tests a longer course of remdesivir plus Paxlovid (nirmatrelvir/ritonavir) for immunocompromised people with persistent COVID-19. It aims to see if combining these two antiviral medicines can help clear the virus more effectively.
This trial looks at how well an antiviral works in the body when started early in people with COVID-19 symptoms. You may be able to join if you’re an otherwise healthy adult with confirmed infection and symptoms for less than 4 days.
This study observes people at higher risk for severe COVID-19 who take Paxlovid, to better understand how well it works and how safe it is in real-world use. It may help doctors confirm the best way to use Paxlovid and spot any side effects.
This study checks how Paxlovid works in everyday care for people who are hospitalized with confirmed COVID-19. If you have a positive COVID-19 test and mild to moderate symptoms, this trial may help doctors understand how well the treatment performs outside of tightly controlled settings.
This study looks at how well a COVID-19 booster works in adults who need long-term medicines that lower immune response. It aims to see whether immunosuppressed people benefit from booster vaccination safely.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.